Abingdon Health Limited (ABDX) ORD GBP0.00025
Share news, reports & tips
28 June 2022 11:19
(Sharecast News) - Rapid testing kits manufacturer Abingdon Health has reached a settlement agreement with the Department for Health and Social Care on outstanding invoices payable to the group for lateral...
17 May 2022 12:51
(Sharecast News) - Rapid test developer and manufacturer Abingdon Health announced a "significant contract" with a European customer on Friday, for the production of lateral flow device (LFD)...
23 August 2021 07:43
(Sharecast News) - Abingdon Health surged on Monday after launching a Covid-19 antibody self-test it manufactured with BioSure.
12 August 2021 09:15
(Sharecast News) - Covid-19 test kit manufacturer Abingdon Health warned on Thursday that full-year revenues would be at the bottom end of forecasts.
27 April 2021 09:54
(Sharecast News) - Abingdon Health warned on Tuesday that it looked set to post a full-year underlying loss despite stating it had continued to make progress on commercialising its AbC-19TM rapid test in the...
10 March 2021 09:27
(Sharecast News) - Rapid tests developer Abingdon Health has signed a non-exclusive sales and distribution agreement in the UK and Europe for its AbC-19 rapid neutralising antibody test with BioSure UK.
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2022. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.